• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Septerna Announces Initiation of Ph 1 Clinical Trial of SEP-479

    GLOBENEWSWIRE

    Septerna Highlights Pipeline, Reports Q4 2025 & FY Results

    GLOBENEWSWIRE

    Septerna`s SEP-631 Succeeds in Phase 1 for Mast Cell Therapy

    GLOBENEWSWIRE

    Septerna To Present At TD Cowen Health Care Conference

    GLOBENEWSWIRE

    Septerna Unveils Phase 1 SEP-631 Data for Mast Cells at 2026

    GLOBENEWSWIRE

    Septerna Grants Inducement Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Septerna Appoints Mark A. Wilson As Chief Legal Officer

    GLOBENEWSWIRE

    Septerna To Present At J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Septerna To Attend Evercore Healthcare Conference

    GLOBENEWSWIRE

    Septerna Showcases Progress, Reveals Q3 2025 Financials

    GLOBENEWSWIRE

    Septerna To Participate In Upcoming Investor Conferences

    GLOBENEWSWIRE

    Septerna Appoints Keith Gottesdiener, As Board Director

    GLOBENEWSWIRE

    Septerna Begin Ph1 Trial of SEP-631 for Mast Cell-Driven Diseases

    GLOBENEWSWIRE

    Septerna Reports Q2 2025 Financial Results and Business Progress

    GLOBENEWSWIRE

    Septerna to Present at Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Septerna to Present at TD Cowen Health Care Conference

    GLOBENEWSWIRE

    Septerna drops lead asset over side effects 4 months after IPO

    GLOBENEWSWIRE

    Septerna to Present at 43rd J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Septerna Reports Q3 2024 Financial Results And Business Highlights

    GLOBENEWSWIRE

    Septerna Announces Closing of $331.2 Million Upsized IPO

    GLOBENEWSWIRE

    Septerna Prices Upsized Initial Public Offering

    GLOBENEWSWIRE

    Septerna plans $158M IPO to fund readouts for GPCR pipeline

    FIERCE BIOTECH

    GPCR firm Septerna files for IPO on strength of preclinical data

    FIERCE BIOTECH

    Septerna Presents New Preclinical Data For PTH1R Agonists

    BUSINESSWIRE

    Septerna Announces Phase 1 Trial With SEP-786 For Treatment

    BUSINESSWIRE

    Septerna Appoints Veterans In Drug Development Roles

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.